866-997-4948(US-Canada Toll Free)

Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

Published By :

GlobalData

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 44 Pages

Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017" provides an overview of Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Chylomicronemia (Type I Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 18
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Familial Chylomicronemia (Type I Hyperlipoproteinemia) 32
Jul 11, 2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome 32
Clinical Trial Profile Snapshots 33
Appendix 42
Abbreviations 42
Definitions 42
Research Methodology 43
Secondary Research 43
About GlobalData 44
Contact Us 44
Source 44

List of Tables
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 15
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 19
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31

List of Figures
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 15
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 18
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
GlobalData Methodology 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *